Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc.
April 08 2015 - 8:00AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it
has completed the previously announced planned acquisition of
Flexus Biosciences, Inc.
The transaction includes full rights to F001287, Flexus’ lead
preclinical, small-molecule IDO1-inhibitor targeted for IND filing
in the second half of 2015 and an IDO/TDO discovery program that
includes its IDO-selective, IDO/TDO dual and TDO-selective compound
libraries. A newly formed entity established by the current
shareholders of Flexus will retain, from and after the closing, all
non-IDO/TDO assets of Flexus including those related to Flexus’
Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule
Treg cancer immunotherapy programs, and its current personnel and
facilities.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit www.bms.com or follow us on Twitter at
http://twitter.com/bmsnews.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements"
relating to the acquisition of Flexus by Bristol-Myers Squibb and
the discovery, development and commercialization of certain
investigational compounds. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee
that the expected benefits of the acquisition will be realized. In
addition, the compounds described in this release are subject to
all the risks inherent in the drug development process, and there
can be no assurance that the development of these compounds will be
successful. Forward-looking statements in the press release should
be evaluated together with the many uncertainties that affect
Bristol-Myers Squibb's business, particularly those identified in
the cautionary factors discussion in Bristol-Myers Squibb's Annual
Report on Form 10-K for the year ended December 31, 2014, its
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
Bristol-Myers Squibb undertakes no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events, or otherwise.
Bristol-Myers SquibbMedia:Ken Dominski, 609-252-5251,
ken.dominski@bms.comSarah Koenig, 609-252-4145,
sarah.koenig@bms.comorInvestors:Ranya Dajani, 609-252-5330,
ranya.dajani@bms.comorFlexusMedia and InvestorsYujiro Hata,
Flexus Chief Operating Officer, 650-489-9009,
yhata@flexusbio.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024